Life Science Investing Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
Galectin Therapeutics Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA
pharmaceutical investing Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
Providence Gold Mines: Unlocking Untapped, High-grade Gold Deposits in the historic Mother Lode Gold Belt in California
